ELI LILLY & CO. (NY:LLY)
35.20
+0.42 (1.21%)
| ELI LILLY & CO. (NY:LLY) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $34.78 | 52 Week High | $38.40 | ||
| Open | $34.95 | 52 Week Low | $27.21 | ||
| Day High | $35.47 | P/E | N/A | ||
| Day Low | $34.86 | EPS | $-0.19 | ||
| Volume | 10,261,548 | ||||
| More LLY Info: Chart SEC Filings Profile Historical Options | |||||
Eli Lilly & Co. Summary
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of pharmaceutical products in the United States, Puerto Rico, and internationally. The company offers neuroscience products, endocrine products, oncology products, and cardiovascular agents for the treatment of various ...more
Executives
Sidney Taurel - Chairman, CEO
Links
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| AMLN | 19 | ALKS | 13 |
| PFE | 10 | MRK | 7 |
| BMY | 6 | MRK | 6 |
| WFC | 4 | KEY | 4 |
| MO | 4 | STJ | 3 |
| GSK | 3 | BAC | 3 |
Entities who have mentioned LLY
- UBS | View Related Stories »
- Citi | View Related Stories »
- Dividend | View Related Stories »
- JPMorgan | View Related Stories »
- Banc of America | View Related Stories »
- Credit Suisse | View Related Stories »
- Morgan Stanley | View Related Stories »
- Carl Icahn | View Related Stories »
- Crude Oil | View Related Stories »
- Deutsche Bank | View Related Stories »
- Ben S. Bernanke | View Related Stories »
- Jefferies & Co | View Related Stories »
- Trading Radar | View Related Stories »
- Wachovia | View Related Stories »
- Soleil Securities | View Related Stories »
- Goldman Sachs | View Related Stories »
- David Moenning | View Related Stories »
- Piper Jaffray | View Related Stories »
- Merrill Lynch | View Related Stories »
- Bankruptcy | View Related Stories »
- Robert W Baird | View Related Stories »
- Notable Analyst Rating Changes | View Related Stories »
- Argus | View Related Stories »
- Bear Stearns | View Related Stories »
- Goldman Sachs Conviction Sell List | View Related Stories »
View All Major News StreetInsider.com Major News for LLY
- Eli Lilly (LLY) Posts Q4 EPSo f $0.91, Misses Views by 1c; Reaffirms FY10 EPS Guidance
- Eli Lilly & Co (LLY) Tops Q3 EPS by 18c; Guides FY Above the Street
- Eli Lilly (LLY) Phase III Study of Arzoxifene Fails to Demonstrate Statistically Significant Difference; Updates EPS Guidance
View All ReportsStreetInsider.com Reports on LLY
- Lilly's (LLY) Cymbalta Shows Ability to Reduce Chronic Lower Back Pain
- Starpharma Signs Collaborative Research Agreement with Eli Lilly (LLY)
- Eli Lilly (LLY) Posts Q4 EPSo f $0.91, Misses Views by 1c; Reaffirms FY10 EPS Guidance
- Trading Radar for 01/28: Amazon.com (AMZN), Microsoft (MSFT), Chubb (CB), AT&T (T), Ford Motor (F), L-3 (LLL) Report
- Eli Lilly (LLY) puts more active than calls into EPS
View All Press ReleasesCompany Press Releases on LLY
- Lilly's Online, Interactive Health Education Program Receives Two Web Awards
- Cymbalta(R) Significantly Reduced Chronic Low Back Pain in New Study
- Starpharma and Lilly Sign New Drug Delivery Collaboration for Human Pharmaceuticals
- Lilly Reports Fourth-Quarter and Full-Year 2009 Results
- A Fibromyalgia Drug That Improves Sleep Quality More Than Pfizer's Lyrica Would Earn Sizeable Patient Share in the U.S. and Europe
StreetInsider Reports on LLY by Category
View All BlogsBlogs on LLY
- Four Stock Ideas as the Market Searches for Support
- Wild Weekly Wrap-Up: Everyone Just Relax
- How Big Pharma Got in This Fix
- Eli Lilly and Glaxo SmithKline: A Tale of Two Different Pharmas
- Eli Lilly and GlaxoSmithKline: A Tale of Two Different Pharmas
View All FilingsSEC Filings on LLY
- Form 4 LILLY ELI & CO For: Feb 03 Filed by: Rice Derica W
- Form 4 LILLY ELI & CO For: Feb 01 Filed by: Lundberg Jan M
- Form 4 LILLY ELI & CO For: Feb 01 Filed by: Rice Derica W
- Form 4 LILLY ELI & CO For: Feb 01 Filed by: PAUL STEVEN M
- Form 4 LILLY ELI & CO For: Feb 01 Filed by: LECHLEITER JOHN C
Comments on LLY
No comments are currently available.
on Jan 21, 2010
at 02:49 AM louboutin http://www.bootboots.com http://www.salelouboutin.com http://www.buylouboutin.com http://www.bestlouisvuitton.com http://www.sale-mbt.com http://www.luxurybootsconsale.com http://www.discount-christianlouboutin.com
Article: Amylin Pharmaceuticals (AMLN) Sees Upside Action
on Jan 21, 2010
at 02:49 AM louboutin http://www.bootboots.com http://www.salelouboutin.com http://www.buylouboutin.com http://www.bestlouisvuitton.com http://www.sale-mbt.com http://www.luxurybootsconsale.com http://www.discount-christianlouboutin.com
Article: Amylin Pharmaceuticals (AMLN) Sees Upside Action
on Jan 21, 2010
at 02:49 AM louboutin http://www.bootboots.com http://www.salelouboutin.com http://www.buylouboutin.com http://www.bestlouisvuitton.com http://www.sale-mbt.com http://www.luxurybootsconsale.com http://www.discount-christianlouboutin.com
Article: Amylin Pharmaceuticals (AMLN) Sees Upside Action
on Dec 17, 2009
at 01:44 PM Zyprexa side effect issues prevail Lilly needs to resolve issues with the Zyprexa original formula. Eli Lilly sells a drug (Zyprexa) that can cause diabetes and then turn a profit on the drugs that treat the condition that they may have caused in the first place! Eli Lilly has made $38 billion on Zyprexa and it was way oversold and caused diabetes and in some cases sudden death. Eli Lilly has received a huge criminal fine over their Zyprexa cash cow,add it all up comes to $4.6 billion, in Zyprexa settlements,fines,litigation. ---- Daniel Haszard Zyprexa whistle-blower
Article: FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
on Dec 16, 2009
at 08:54 PM Generex Biotech (GNBT) Looks extremely positive.
Article: UBS Modestly Positive On US Large-Cap Pharma (MRK, PFE, BMY, LLY)